Nomura Holdings Inc. Invests $56.82 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Nomura Holdings Inc. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 307,800 shares of the medical research company’s stock, valued at approximately $56,820,000. Nomura Holdings Inc. owned approximately 0.60% of Charles River Laboratories International as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Optiver Holding B.V. purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $37,000. GeoWealth Management LLC grew its stake in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $48,000. Finally, Tortoise Investment Management LLC grew its stake in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $144.38 on Wednesday. The firm has a market cap of $7.09 billion, a PE ratio of 962.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average is $137.41 and its two-hundred day moving average is $165.78.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the business earned $2.27 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CRL shares. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average price target of $176.00.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Birgit Girshick acquired 1,514 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).